The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption
|Hyperlipidemia Cardiovascular Disease Diet Therapy||Procedure: Diet with polyfructans and viscous fibers or soy protein||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption on Blood Lipids Risk Factors for Heart Disease in Healthy "Normal" and Hyperlipidemic Subjects|
- Total and LDL cholesterol, Total:HDl cholesterol ratio
- antropometrics: body weight, blood pressure, blood: triglycerides, fecal: SCFA and microbiology, breath: gases, urine: soy isoflavones, creatinine, urea, electrolytes
Design: Studies will be three phase randomized crossover design with all subjects undergoing all three phases. Each phase will be one month in duration with at least 2-4 weeks washout between phases.
General Protocol: Both dietary studies (Study 1 fiber plus polyfructans; and Study 2 soy plus polyfructans) will follow the same general protocol. Supplements and measurements will differ between studies. Diets will be self-selected low-fat diets throughout (<7% of total energy as saturated fat and, <200 mg/d dietary cholesterol). Supplements will be provided at weekly intervals. At the start and at two weekly intervals during the study body weight, blood pressure and fasting bloods will be taken together with 24h urine and 4-day fecal collections and samples for fecal microbiology to be obtained during week 4. Treatments: Both studies will involve a control diet which will be an NCEP step 2 diet (low in saturated fat and dietary cholesterol) with 10-20 g inulin. Study 1 subjects will take 10-15 g viscous fiber foods with or without the fructan. Study 2 subjects will take 30-40 g soy protein foods with or without the fructan (please see Table 1). The supplements will be provided as foods: oat bran bread to be taken with meals and as snacks during Study 1 and soy protein to be taken in soy beverage, soy hot dogs, burgers, tofu, etc., during Study 2.
Study Details: Subjects will come after a 12h overnight fast to the Risk Factor Modification Centre at St. Michael's Hospital immediately prior to commencement of each treatment phase and at weekly intervals during the course of each study period. Prior to the start of the study, subjects will be instructed on details of the study diet protocol. They will also be asked to maintain a constant level of physical activity throughout the course of the study. At all visits, body weight (in kg) will be obtained in indoor clothing, without shoes, and blood pressure will be taken twice in the dominant arm after subjects have been seated for at least 20 minutes. Height (in cm) will be recorded at the first visit. Throughout the study period, subjects will maintain their usual diet, which should be an NCEP step 2 diet (low saturated fat). Subjects will provide a fasting blood sample at week 0 and at weekly periods throughout the study. At weeks 0, and 4 seven-day food records will be collected. Subjects will also be weighed and seated blood pressure will be taken. Breath samples, 24h urine and 4-day fecal collections will be made at the beginning of the study and at the end of each study phase.
Diets: Initial dietary records prior to the start of the study together with instruction from the dietitian will ensure all subjects are on low fat (<7% of energy from saturated fat), low cholesterol diets (<200 mg/d), which they will maintain throughout the study. During the study subjects will collect their supplements at weekly intervals and return uneaten supplements. Subjects will be provided with self-tarring scales and diet history forms on which to record all food eaten together with the weights of all food items consumed during each study phase. These will be checked by the dietitian at weekly intervals to ensure compliance with the diet plan and to ensure there are no changes in body weight. Photocopies of the first week's diet record will be provided to each subject at the start of each phase to act as a dietary template and ensure consistency between studies. Compliance: This will be assessed by the return of uneaten supplements which will be weighed at the end of each phase and from the completed weekly check lists of supplements eaten and seven day diet records.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00516594
|Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Health Centre|
|Toronto, Ontario, Canada, M5C 2T2|
|Principal Investigator:||David JA Jenkins, MD, PHD, DSc||University of Toronto and St. Michael's Hospital|